by Sayer Ji

GreenMedInfo.com

A devastating new report commissioned by the National Cancer Institute reveals that our 40-year long ‘War on Cancer’ has been waged against a vastly misunderstood ‘enemy,’ that in many cases represented no threat to human health whatsoever.

If you have been following our advocacy work on cancer, particularly in connection with the dark side of breast cancer awareness month, you know that we have been calling for the complete reclassification of some types of ‘breast cancer’ as benign lesions, e.g. ductal carcinoma in situ (DCIS), as well as pointing out repeatedly that x-ray based breast screenings are not only highly carcinogenic but are also causing an epidemic of “overdiagnosis” and “overtreatment” in US women, with an estimated 1.3 million cases in the past 30 years alone.

[Just recently], a National Cancer Institute commissioned panel’s report published in JAMA online confirmed that we all – public and professionals alike – should stop calling low-risk lesions like DCIS and high-grade prostatic intraepithelial neoplasia (HGPIN) ‘cancer.’

There are wide-reaching implications to this recommendation, including:

Millions of women in this country have been diagnosed with DCIS, and millions of men with HGPIN, and subsequently [mis]treated. Are they now to be retroactively reclassified as ‘victims’ of iatrogenesis, with legal recourse to seek compensation?

Anyone engaged in a cancer screening will now need to reconsider and weigh both the risks and benefits of such a ‘preventive’ strategy, considering that the likelihood of being diagnosed with a false positive over 10 years is already over 50% for women undergoing annual breast screening .

. The burgeoning pink ribbon-bedecked ‘breast cancer awareness’ industry will be forced to reformulate its message, as it is theoretically culpable for the overdiagnosis and overtreatment of millions of US women by propagating an entirely false concept of ‘cancer.’

As reported by Medscape:

The practice of oncology in the United States is in need of a host of reforms and initiatives to mitigate the problem of overdiagnosis and overtreatment of cancer, according to a working group sanctioned by the National Cancer Institute. Perhaps most dramatically, the group says that a number of premalignant conditions, including ductal carcinoma in situ and high-grade prostatic intraepithelial neoplasia, should no longer be called “cancer.” Instead, the conditions should be labeled something more appropriate, such as indolent lesions of epithelial origin (IDLE), the working group suggests. The Viewpoint report was published online July 29 in JAMA.

Fundamentally, overdiagnosis results from the fact that screen-detected ‘cancers’ are disproportionately slower growing ones, present with few to no symptoms, and would never progress to cause harm if left undiagnosed and untreated.

As you can see by the graph above, it is the fast-growing tumors which will be more difficult to ‘detect early,’ and will progress rapidly enough to cause symptoms and perhaps even death unless treated aggressively. But even in the case of finding the tumor early enough to contain it through surgery, chemotherapy and/or radiation, it is well-known that the minority subpopulation of cancer stem cells within these tumors will be enriched and therefore made more malignant through conventional treatment. For instance, radiotherapy radiation wavelengths were only recently found by UCLA Jonnsson Comprehensive Cancer Center researchers to transform breast cancer cells into highly malignant cancer stem-cell like cells, with 30 times higher malignancy post-treatment.

What this means is that not only are millions of screen-detected abnormalities not ‘cancer’ in the first place but even those which can be considered fast-growing are often being driven into greater malignancy by the conventional chemotherapy, radiation and surgery-based standard of cancer care itself.

Our entire world view of cancer needs to shift from an enemy that “attacks” us and that we must wage war against, to something our body does, presumably to survive an increasingly inhospitable, nutrient-deprived, carcinogen- and radiation-saturated environment, i.e. Cancer As An Ancient Survival Mechanism Unmasked.

When we look at cancer through the optic of fear and see it as an essentially chaos-driven infinitely expanding mass of cells, we are apt to make irrational choices. The physiological state of fear itself has been found to activate multidrug resistance proteins within cancer cells, explaining how our very perception of cancer can influence and/or determine its physiological status and/or trajectory within our body.

The NCI panel report opined:

“The word “cancer” often invokes the specter of an inexorably lethal process; however, cancers are heterogeneous and can follow multiple paths, not all of which progress to metastases and death, and include indolent disease that causes no harm during the patient’s lifetime.”

Read the full article here: http://www.greenmedinfo.com/blog/millions-wrongly-treated-cancer-national-cancer-institute-panel-confirms

See Also:

We Lost the War on Cancer – Review of Alternative Cancer Therapies



eBook

Retail : $999

Now : $599

We have lost the war on cancer. At the beginning of the last century, one person in twenty would get cancer. In the 1940s it was one out of every sixteen people. In the 1970s it was one person out of ten. Today one person out of three gets cancer in the course of their life.

The cancer industry is probably the most prosperous business in the United States. In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research, such as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care are $125 billion, with a projected 39 percent increase to $173 billion by 2020.

The simple fact is that the cancer industry employs too many people and produces too much income to allow a cure to be found. All of the current research on cancer drugs is based on the premise that the cancer market will grow, not shrink.

John Thomas explains to us why the current cancer industry prospers while treating cancer, but cannot afford to cure it in Part I. In Part II, he surveys the various alternative cancer therapies that have been proven effective, but that are not approved by the FDA.

Read We Lost the War on Cancer – Review of Alternative Cancer Therapies on your mobile device! Order Here

Purchase the DVD – Free Shipping Available! Click image to view the trailer.



